Human gene therapy products include naked DNA and viral as well as non-viral vectors containing nucleic acids.
There is limited experience on the preclinical toxicity studies necessary for the safety evaluation of these products, which have been outlined in several recently released guidelines.
Requirements for the preclinical safety evaluation of human gene therapy products are both specific and non-specific.
All key preclinical studies should be performed in compliance with Good Laboratory Practices.
Non-specific requirements are in fact common to all pharmaceutical products.
Critical specific issues to be addressed are : the safety evaluation of the vector and the toxicity of the expressed protein (s), which are the two components of gene therapy products, the quality of the test article, the selection of animal species, and the verification that the administration method successfully transports the gene of interest, with the vector, to the target site (s).
The treatment schedule should mimic the intended human therapeutic design.
The host's immune response against the gene therapy product has to be evaluated to detect possible adverse effects and immune neutralization by antibodies.
The biodistribution of the gene of interest is also essential and can be evaluated by molecular biology techniques, such as PCR.
Specific confinement is required for the safe manipulation of viral vectors.
Mots-clés Pascal : Sécurité, Evaluation, Réglementation, Toxicité, Essai préclinique, Thérapie génique, Homme
Mots-clés Pascal anglais : Safety, Evaluation, Regulation, Toxicity, Preclinical trial, Gene therapy, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0421301
Code Inist : 002A31D01D. Création : 22/03/2000.